Please take the time to explain to me how INSM is different from ECYT as it pertains to the market and Greg Wade. You waste our time here yet NEVER offer a reasonable explanation to what the FACTS are. Both companies have promising drug(s) that may be approved near term. Wade's PT for Insmed was $7 when it was $19 (so that is a -$12). His PT for ECYT was $65 when it was $28 (and then had a secondary for $21). (so that is a +$37). Insmed has lost $7 since his PT in Feb and March. Endocyte has lost $11 (wrong direction) since his PT in March. He is off by $5.50 on INSM and he is off $48 (yes FORTY EIGHT) on ECYT.